First, given that (as Andrew Matzkin of Health Advances observed) the Flatiron transaction is “putting smiles on a lot of faces,” what other emerging oncology clinical data companies might soon be in play? And second, more fundamentally, what are the implications of the rise of these types of companies – for both pharma and for healthcare?
